DMD is a severe neuromuscular disorder resulting from deficiency of the functional dystrophin protein.4 Ataluren promotes the production of full-length dystrophin via read-through of an in-frame premature stop codon, and it is indicated for the treatment of patients with nmDMD.20,21 To the best of our knowledge, this is the first report of long-term ataluren treatment in patients with nmDMD from the Kingdom of Saudi Arabia. The gene discussed is DMD; the disease is Duchenne muscular dystrophy.